Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

H1N1 flu fight gets $1.5 billion in Senate supplemental funding bill

This article was originally published in The Gray Sheet

Executive Summary

Senate approves $1.5 billion to combat the H1N1 flu virus as part of an FY 2009 war supplemental appropriations bill, S. 1054, including funds for H1N1 influenza diagnostics and personal protective equipment ("1The Gray Sheet" May 4, 2009, p. 3). The Senate voted 86 to 3 to pass the bill May 21. A similar supplemental appropriations bill in the House (H.R. 2346), which passed May 14 in a 368 to 60 vote, allows $1.85 billion to prepare and respond to a possible pandemic of H1N1 flu. House and Senate conferees will have to resolve differences when they return to Washington June 1

You may also be interested in...



Push For Rapid Diagnostics, Protective Equipment Amid Flu Outbreak

Government health officials and industry are scrambling to identify and release diagnostics technology that can quickly identify patients stricken with the hybrid flu virus sweeping the globe, while demand for respirators and other personal protective equipment is rising

California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation

CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.

CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales

Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027502

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel